Business Context and Reporting Period
Company: DaVita Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: August 25, 2006
Event: Entry into a Material Definitive Agreement.
On August 25, 2006, DaVita Inc. entered into an Amended and Restated Alliance and Product Supply Agreement with Gambro Renal Products Inc. and its parent, Gambro AB. This agreement supersedes a termination notice DaVita issued on May 29, 2006, regarding the original supply agreement.
Key Financial Metrics
This filing is a Current Report (Form 8-K) regarding a contractual agreement and does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity data. The filing text does not provide a clear value for any financial metrics.
Material Changes Versus Prior Period
The filing details a material change in the Company's supply chain obligations compared to the Original Supply Agreement dated October 5, 2005:
- Revocation of Termination: The new agreement effectively revokes DaVita's May 29, 2006, notice of termination, which was based on Gambro's alleged material breach due to an FDA import ban.
- Supply Flexibility: During the FDA import ban and for a period thereafter, DaVita is permitted to secure alternate sources of supply for affected products.
- Reduced Obligations: The Company's obligation to purchase a significant majority of its hemodialysis products, supplies, and equipment from Gambro has been reduced.
- Termination Rights: DaVita may terminate obligations for specific products if Gambro materially breaches the agreement. Additionally, if the FDA import ban is not lifted by June 30, 2007, DaVita may terminate obligations for the affected products.
Guidance, Outlook, Risks, and Contingencies
Management Commentary and Risks:
- Forward-Looking Statements: The filing contains forward-looking statements subject to known and unknown risks that could cause actual results to differ materially.
- Regulatory Contingency: The agreement is contingent on the status of the U.S. Food and Drug Administration (FDA) import ban. If the ban persists beyond June 30, 2007, DaVita retains the right to terminate specific purchase obligations.
- Reference to Other Filings: Detailed risks are referenced in the Company's Quarterly Report on Form 10-Q for the quarter ended June 30, 2006. The full text of the Amended Supply Agreement will be filed as an exhibit to the Form 10-Q for the quarter ended September 30, 2006.
Important Facts for Investor Verification
- Verify the specific terms of the reduced purchase obligations in the full Amended Supply Agreement (to be filed in the Q3 2006 Form 10-Q).
- Monitor the status of the FDA import ban affecting Gambro Renal Products to assess the likelihood of DaVita exercising its termination right by June 30, 2007.
- Review the Q2 2006 Form 10-Q for a comprehensive list of risks associated with the Company's supply chain and forward-looking statements.
- Confirm the impact of the supply agreement amendment on future operating costs and margins, as this filing does not quantify financial impacts.